LifeSciVC

Dual Wielding in I&I: A Pivotal Year Ahead

The article argues that the next breakthrough in immunology and inflammation (I&I) therapeutics will come from multi‑drug and multi‑target strategies rather than single‑target antibodies, which have hit an efficacy ceiling. It traces the evolution from early blockbuster biologics like Humira to today’s crowded pipeline of ~50 antibodies, highlighting modest efficacy gains across indications. Industry leaders are now investing heavily in combination biologics and bispecific antibodies, with roughly 25% of late‑stage I&I assets falling into these categories. 2026 is positioned as a decisive year, as several large Phase 2/3 trials will test whether dual‑target approaches can finally break the ceiling.